Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.8735 EUR -0.8% Market Closed
Market Cap: 592.5m EUR
Have any thoughts about
Pharming Group NV?
Write Note

P/E
Price to Earnings

-34.7
Current
-31.9
Median
22.1
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-34.7
=
Market Cap
592.7m EUR
/
Net Income
-17.8m USD
All Countries
Close
Market Cap P/E
NL
Pharming Group NV
AEX:PHARM
592.7m EUR -34.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 740.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 62
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 33.5
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 923.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD -217.7
US
Epizyme Inc
F:EPE
94.1B EUR -472.7
AU
CSL Ltd
ASX:CSL
135.7B AUD 32.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 16.9
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
36B EUR -135.6
Earnings Growth P/E to Growth
NL
Pharming Group NV
AEX:PHARM
Average P/E: 213.6
Negative Multiple: -34.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-83
2-Years Forward
P/E
-90.8
3-Years Forward
P/E
44.3

See Also

Discover More